Breaking News, Collaborations & Alliances

Amgen, Servier Complete Product Pact

Split up cardiovascular assets

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amgen and Servier have completed their cardiovascular product collaboration agreement from July 8, 2013. Amgen has obtained U.S. commercial rights to Servier’s novel oral drug, approved in the EU as Procoralan (ivabradine) for chronic heart failure and stable angina in patients with elevated heart rates. Amgen has also received an exclusive option to develop and commercialize Servier’s investigational molecule, S38844, for cardiovascular diseases in the U.S. S38844 is currently in Ph...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters